| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d057deeb409bb67122c4c90b35ea342a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1bba710e7aaa56d8ab15a910fcd3dc5f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_20f06a8bbcd59fe022997403718174c8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_81ea6deb0388c62ef8bc8e4975493bd6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_229abb6865372275288c1bdac0527975
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3cd35caf6c3c0e743f2f4d6b17062120 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate |
2012-05-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_32262867c1d7ef9e98aacd66f24dab31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_26f14a4741916bfb05e5c26fd02dd6c3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_80cccb49141c4f3f1d4a532ab6481dfc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a5cd88d7c27d44f92513af9fae21ffd0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_27ce2a82b459cf0bf2863c0170a48a9e |
| publicationDate |
2012-11-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2012154452-A1 |
| titleOfInvention |
Stratification, therapies, targeted treatment and prevention of life-threatening ventricular tachya |
| abstract |
Systems And Methods for risk stratification, therapies, targeted treatment and prevention of life-threatening ventricular tachyarrhythmias and sudden cardiac death for patients with congenital type-1 long QT syndrome (LQT1) is disclosed. Genetic testing to identify genetic mutations indicative of long QT syndrome is performed, with KCNQl channel C-loop missense mutations being separated from other mutations. The KCNQl channel C-loop missense mutations are an indicator of improved response to beta blocker therapy over other mutations responsible for genetic long QT syndrome. The use of such genetic testing data and targeted risk stratification is useful in determining the composition of a therapeutic agent, taking a therapeutic action, determining the optimal therapeutic efficacy of a drug for the treatment of long QT syndrome, determining a response to beta blocker therapy for patients with genetic long QT syndrome, and the like. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110022908-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107011444-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107011444-A |
| priorityDate |
2011-05-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |